Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang NHU Company Ltd. (002001.SZ)
Xinchang, CN
Zhejiang NHU Company Ltd., founded in 1999 and headquartered in Xinchang, China, specializes in the nationwide production and distribution of a broad spectrum of chemical products. Its principal operations are divided into four main categories: 1. Nutritional Products: The company offers a comprehensive range of supplements, including essential vitamins (E, A, C, D3, biotin), DL-Methionine, coenzyme Q10, and various carotenoids. These ingredients are critical for enhancing animal feed and fortifying food, beverages, and health-related products. 2. Flavors and Fragrances: This segment supplies a variety of aroma chemicals, such as derivatives from the linalool and citral series, cis-3-hexenol, methyl dihydrojasmonate, raspberry ketone, and ligustral, which are widely utilized in personal care items, cosmetic formulations, and food flavorings. 3. New Polymer Materials: Zhejiang NHU provides advanced polymer solutions like polyphenylene sulfide and polyphthalamide. These materials find essential applications across industries including electronics, automotive manufacturing, and environmental protection. 4. Active Pharmaceutical Ingredients (APIs): The company manufactures crucial pharmaceutical components, including moxifloxacin hydrochloride, vitamin A, and vitamin D3, which serve as foundational substances for the development and production of various drug preparations.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.45% | -1.18% | -8.44% | +10.74% | +32.15% | +32.99% | +52.00% | +103.65% | +24.86% | +312.56% | +6,251.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 3 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.0% Q1'26: +15.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+15.7% Q1'26: -1.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+29.8% ★ Q1'26: +21.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+36.3% ★ Q1'26: +34.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+25.3% ★ Q1'26: +23.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q1'26: -1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.47× ★ Q1'26: 0.88× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 1 EPS Ana. |
Dec 2027 9 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.82B
est: 3.98B (-4.1%)
|
4.70B
est: 4.80B (-2.2%)
|
6.24B
est: 6.13B (+1.7%)
|
8.68B
est: 9.35B (-7.1%)
|
7.66B
est: 7.61B (+0.7%)
|
10.31B
est: 10.72B (-3.8%)
|
14.92B
est: 13.72B (+8.8%)
|
15.93B
est: 15.83B (+0.6%)
|
15.12B
est: 15.23B (-0.7%)
|
21.61B
est: 21.77B (-0.8%)
|
22.25B
est: 23.04B (-3.4%)
|
26.78B
24.78B – 29.25B
+16.2% YoY
|
27.88B
24.34B – 32.62B
+4.1% YoY
|
30.20B
27.15B – 34.16B
+8.3% YoY
|
| EBITDA |
788.84M
est: 1.60B (-50.7%)
|
1.75B
est: 1.93B (-9.1%)
|
2.55B
est: 2.46B (+3.8%)
|
3.95B
est: 3.75B (+5.3%)
|
2.99B
est: 3.05B (-2.0%)
|
5.04B
est: 4.30B (+17.1%)
|
6.32B
est: 5.50B (+14.9%)
|
5.51B
est: 6.35B (-13.3%)
|
4.84B
est: 6.11B (-20.9%)
|
9.26B
est: 8.64B (+7.2%)
|
10.37B
est: 9.14B (+13.4%)
|
10.62B
9.83B – 11.60B
+16.2% YoY
|
11.06B
9.66B – 12.94B
+4.1% YoY
|
11.98B
10.77B – 13.55B
+8.3% YoY
|
| EBIT |
411.45M
est: 1.23B (-66.4%)
|
1.41B
est: 1.48B (-4.9%)
|
2.18B
est: 1.89B (+15.8%)
|
3.49B
est: 2.88B (+21.5%)
|
2.43B
est: 2.34B (+3.7%)
|
4.17B
est: 3.30B (+26.6%)
|
5.10B
est: 4.22B (+20.8%)
|
4.12B
est: 4.87B (-15.5%)
|
3.13B
est: 4.68B (-33.1%)
|
7.05B
est: 6.52B (+8.2%)
|
8.07B
est: 6.89B (+17.1%)
|
8.01B
7.42B – 8.75B
+16.2% YoY
|
8.34B
7.28B – 9.76B
+4.1% YoY
|
9.04B
8.12B – 10.22B
+8.3% YoY
|
| Net Income |
402.07M
est: 387.91M (+3.7%)
|
1.20B
est: 1.03B (+16.7%)
|
1.70B
est: 1.89B (-9.9%)
|
3.08B
est: 3.17B (-2.9%)
|
2.17B
est: 2.24B (-3.3%)
|
3.56B
est: 3.71B (-4.0%)
|
4.36B
est: 4.31B (+1.1%)
|
3.62B
est: 3.81B (-5.0%)
|
2.70B
est: 2.49B (+8.7%)
|
5.87B
est: 5.82B (+0.9%)
|
6.76B
est: 6.66B (+1.6%)
|
8.82B
7.66B – 10.32B
+32.4% YoY
|
8.89B
8.23B – 9.47B
+0.9% YoY
|
9.91B
8.61B – 11.60B
+11.4% YoY
|
| SGA |
556.39M
est: 182.24M (+205.3%)
|
616.01M
est: 219.67M (+180.4%)
|
470.82M
est: 280.30M (+68.0%)
|
599.51M
est: 427.63M (+40.2%)
|
608.83M
est: 347.89M (+75.0%)
|
726.53M
est: 490.25M (+48.2%)
|
530.62M
est: 627.31M (-15.4%)
|
626.93M
est: 724.18M (-13.4%)
|
709.39M
est: 696.38M (+1.9%)
|
786.19M
est: 745.19M (+5.5%)
|
287.03M
est: 788.42M (-63.6%)
|
916.39M
848.22M – 1.00B
+16.2% YoY
|
954.34M
833.04M – 1.12B
+4.1% YoY
|
1.03B
929.09M – 1.17B
+8.3% YoY
|
| EPS |
0.15
est: 0.13 (+18.8%)
|
0.45
est: 0.34 (+34.1%)
|
0.64
est: 0.62 (+3.9%)
|
1.00
est: 1.03 (-3.1%)
|
0.70
est: 0.73 (-3.9%)
|
1.15
est: 1.21 (-4.8%)
|
1.41
est: 1.40 (+0.5%)
|
1.17
est: 1.24 (-5.7%)
|
0.87
est: 0.81 (+7.4%)
|
1.91
est: 1.90 (+0.5%)
|
2.21
est: 2.18 (+1.6%)
|
2.88
2.50 – 3.37
+32.4% YoY
|
2.91
2.69 – 3.10
+0.9% YoY
|
3.24
2.81 – 3.79
+11.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.74% | 519.8K | 0.95% |
| 2 | JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L | 0.37% | 85.4K | 0.40% |
| 3 | iShares Agribusiness UCITS ETF ISAG.L | 0.28% | 1.27M | 0.55% |
| 4 | Xtrackers Harvest CSI 300 China A-Shares ETF ASHR | 0.18% | 2.46M | 0.65% |
| 5 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.18% | 255.6K | 0.35% |
| 6 | HSBC MSCI China A UCITS ETF HMCT.L | 0.18% | 241.9K | 0.30% |
| 7 | Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L | 0.18% | 560.8K | 0.65% |
| 8 | iShares MSCI China A UCITS ETF CNYA.L | 0.17% | 5.36M | 0.40% |
| 9 | iShares MSCI China A UCITS ETF CNYE.MI | 0.17% | 177.0K | 0.45% |
| 10 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.17% | 236.6K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bai Shan Hu | Vice-Chairman & President | — | male |
| Guanqun Shi | Chief Financial Officer, Vice President, Secretary & Director | — | male |
| Liying Zhang | Vice President | — | female |
| Xiaobi Wang | Accounting Supervisor | — | female |
| Xue Wen Wang | Vice President & Non-Independent Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002001.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
